CBDa/CBGa
- Category
- Anti-Pathogen, Blocks Excess Cytokines, Blocks Spike Protein Attachment, Blocks Spike Protein Penetration, Inhibits Long-Term Disease, Inhibits Long-Term Side Effects
CBDa CANNABIDIOLIC ACID AND CBGa CANNABIGEROLIC ACID
As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity selection-mass spectrometry was used for the discovery of botanical ligands to the SARS-CoV-2 spike protein. Cannabinoid acids from hemp (Cannabis sativa) were found to be allosteric as well as orthosteric ligands with micromolar affinity for the spike protein. In follow-up virus neutralization assays, cannabigerolic acid and cannabidiolic acid prevented infection of human epithelial cells by a pseudovirus expressing the SARS-CoV-2 spike protein and prevented entry of live SARS-CoV-2 into cells. Importantly, cannabigerolic acid and cannabidiolic acid were equally effective against the SARS-CoV-2 alpha variant B.1.1.7 and the beta variant B.1.351. Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2 (Breemen, 2022).
Reference:
(Breemen, 2022). van Breemen RB, Muchiri RN, Bates TA, Weinstein JB, Leier HC, Farley S, Tafesse FG. Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants. J Nat Prod. 2022 Jan 28;85(1):176-184. doi: 10.1021/acs.jnatprod.1c00946. Epub 2022 Jan 10. PMID: 35007072; PMCID: PMC8768006. https://pubmed.ncbi.nlm.nih.gov/35007072/
